A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

Who May Qualify: - Participants with headaches that meet the diagnostic criteria for migraines according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), with or without aura. - Patients prescribed rimegepant by the attending physician for the treatment of migraines. - Signed willing to sign a consent form form. - Age greater than 18 years. - Not concurrently participating in other interventional clinical studies. Who Should NOT Join This Trial: - Patients diagnosed with secondary headaches. - Patients with severe visual, auditory, language, intellectual, memory, consciousness impairments or other conditions that prevent them from completing the questionnaire and follow-up. - Pregnant or lactating female patients. - Patients deemed by the investigator as unsuitable for participation in the study or unable to complete the 4-week follow-up. - Patients with a known history of hypersensitivity reactions to rimegepant or its components. - Evidence in the medical history suggesting the presence of uncontrolled or unstable cardiovascular diseases (such as ischemic heart disease, coronary artery vasospasm, or cerebrovascular ischemia), or a history of myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transient ischemic attack within the past 6 months before the screening visit. Always talk to your doctor about whether this trial is right for you.